{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:31:54Z","timestamp":1791185514426,"version":"4.1.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,23]],"date-time":"2014-11-23T00:00:00Z","timestamp":1416700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00277-014-2236-4","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T13:17:07Z","timestamp":1417439827000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?"],"prefix":"10.1007","volume":"94","author":[{"given":"Bruno","family":"Bockorny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin A.","family":"Dasanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,23]]},"reference":[{"key":"2236_CR1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001\u20131009","journal-title":"N Engl J Med"},{"key":"2236_CR2","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMp0806479","volume":"359","author":"D Steinberg","year":"2008","unstructured":"Steinberg D (2008) The statins in preventive cardiology. N Engl J Med 359:1426\u20131427","journal-title":"N Engl J Med"},{"key":"2236_CR3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/jcb.22092","volume":"106","author":"K Gauthaman","year":"2009","unstructured":"Gauthaman K, Fong CY, Bongso A (2009) Statins, stem cells, and cancer. J Cell Biochem 106:975\u2013983","journal-title":"J Cell Biochem"},{"key":"2236_CR4","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","volume":"344","author":"PM Ridker","year":"2001","unstructured":"Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr (2001) Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959\u20131965","journal-title":"N Engl J Med"},{"key":"2236_CR5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623\u20131630","journal-title":"Lancet"},{"key":"2236_CR6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","volume":"112","author":"Y Shitara","year":"2006","unstructured":"Shitara Y, Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71\u2013105","journal-title":"Pharmacol Ther"},{"key":"2236_CR7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","volume":"64","author":"P Gazzerro","year":"2012","unstructured":"Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M (2012) Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 64:102\u2013146","journal-title":"Pharmacol Rev"},{"key":"2236_CR8","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00280-013-2326-3","volume":"72","author":"TA Ahmed","year":"2013","unstructured":"Ahmed TA, Hayslip J, Leggas M (2013) Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol 72:1369\u20131374","journal-title":"Cancer Chemother Pharmacol"},{"key":"2236_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9149(00)00910-3","volume":"86","author":"TR Pedersen","year":"2000","unstructured":"Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyorala K, Wedel H (2000) Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86:257\u2013262","journal-title":"Am J Cardiol"},{"key":"2236_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.1997.03550040069040","volume":"278","author":"PR Hebert","year":"1997","unstructured":"Hebert PR, Gaziano JM, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc 278:313\u2013321","journal-title":"J Am Med Assoc"},{"key":"2236_CR11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9343(01)00705-7","volume":"110","author":"LM Bjerre","year":"2001","unstructured":"Bjerre LM, Lelorier J (2001) Do statins cause cancer? A metaanalysis of large randomized clinical trials. Am J Med 110:716\u2013723","journal-title":"Am J Med"},{"key":"2236_CR12","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","volume":"105","author":"MA Pfeffer","year":"2002","unstructured":"Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, Davis BR, Friedman CP, Braunwald E (2002) Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation 105:2341\u20132346","journal-title":"Circulation"},{"key":"2236_CR13","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","volume":"105","author":"RJ Simes","year":"2002","unstructured":"Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A (2002) Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105:1162\u20131169","journal-title":"Circulation"},{"key":"2236_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00052142","volume":"2","author":"MR Law","year":"1991","unstructured":"Law MR, Thompson SG (1991) Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 2:253\u2013261","journal-title":"Cancer Causes Control"},{"key":"2236_CR15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/bmj.308.6925.373","volume":"308","author":"MR Law","year":"1994","unstructured":"Law MR, Thompson SG, Wald NJ (1994) Assessing possible hazards of reducing serum cholesterol. BMJ 308:373\u2013379","journal-title":"BMJ"},{"key":"2236_CR16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1089\/154099903322447710","volume":"12","author":"JA Cauley","year":"2003","unstructured":"Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, Cummings SR, Bauer DC (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health 12:749\u2013756","journal-title":"J Womens Health"},{"key":"2236_CR17","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/cncr.20271","volume":"100","author":"DM Boudreau","year":"2004","unstructured":"Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR (2004) The association between 3-hydroxy-3 methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 100:2308\u20132316","journal-title":"Cancer"},{"key":"2236_CR18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(04)16936-5","volume":"364","author":"TE Strandberg","year":"2004","unstructured":"Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian simvastatin survival study (4S). Lancet 364:771\u2013777","journal-title":"Lancet"},{"key":"2236_CR19","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1056\/NEJMoa043792","volume":"352","author":"JN Poynter","year":"2005","unstructured":"Poynter JN, Gruber SB, Higgins PDR, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184\u20132192","journal-title":"N Engl J Med"},{"key":"2236_CR20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/aje\/kwi203","volume":"162","author":"J Shannon","year":"2005","unstructured":"Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE (2005) Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162:318\u2013325","journal-title":"Am J Epidemiol"},{"key":"2236_CR21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.11-3-306","volume":"11","author":"K Hindler","year":"2006","unstructured":"Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role of statins in cancer therapy. Oncologist 11:306\u2013315","journal-title":"Oncologist"},{"key":"2236_CR22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1055-9965.EPI-05-0866","volume":"15","author":"J Fortuny","year":"2006","unstructured":"Fortuny J, de Sanjos\u00e9 S, Becker N, Maynadi\u00e9 M, Cocco PL, Staines A, Foretova L, Vornanen M, Brennan P, Nieters A, Alvaro T, Boffetta P (2006) Statin use and risk of lymphoid neoplasms: results from the European case-control study EPILYMPH. Cancer Epidemiol Biomark Prev 15:921\u2013925","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2236_CR23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/aje\/kwg004","volume":"157","author":"AB Beiderbeck","year":"2003","unstructured":"Beiderbeck AB, Holly EA, Sturkenboom MC, Coebergh JW, Stricker BH, Leufkens HG (2003) Prescription medications associated with a decreased risk of non-Hodgkin\u2019s lymphoma. Am J Epidemiol 157:510\u2013516","journal-title":"Am J Epidemiol"},{"key":"2236_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/B:CACO.0000027506.55846.5d","volume":"15","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH, Zheng T (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15:419\u2013428","journal-title":"Cancer Causes Control"},{"key":"2236_CR25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.20758","volume":"114","author":"S Friis","year":"2005","unstructured":"Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, S\u00f8rensen HT, Olsen JH (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114:643\u2013647","journal-title":"Int J Cancer"},{"key":"2236_CR26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2125.2007.02959.x","volume":"64","author":"S Bonovas","year":"2007","unstructured":"Bonovas S, Filioussi K, Tsantes A, Sitaras NM (2007) Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. Br J Clin Pharmacol 64:255\u2013262","journal-title":"Br J Clin Pharmacol"},{"key":"2236_CR27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","volume":"343","author":"JL Goldstein","year":"1990","unstructured":"Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425\u2013430","journal-title":"Nature"},{"key":"2236_CR28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1998.8491","volume":"152","author":"K Nakahara","year":"1998","unstructured":"Nakahara K, Kuriyama M, Sonoda Y (1998) Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological and biochemical study. Toxicol Appl Pharmacol 152:99\u2013106","journal-title":"Toxicol Appl Pharmacol"},{"key":"2236_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4615-5901-6_1","volume":"28","author":"SM Jackson","year":"1997","unstructured":"Jackson SM, Ericsson J, Edwards PA (1997) Signalling molecules derived from the cholesterol biosynthetic pathway. Subcell Biochem 28:1\u201321","journal-title":"Subcell Biochem"},{"key":"2236_CR30","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","volume":"120","author":"AF Ward","year":"2012","unstructured":"Ward AF, Braun BS, Shannon KM (2012) Targeting oncogenic Ras signaling in hematologic malignancies. Blood 120:3397\u20133406","journal-title":"Blood"},{"key":"2236_CR31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0145-2126(01)00033-9","volume":"25","author":"J Braess","year":"2001","unstructured":"Braess J, Hiddemann W (2001) The widening role of statins: RAS signal transduction and drug-induced cytotoxicity in human leukemia: a commentary to \u2018interaction of cytosine arabinoside and lovastatin in human leukemia cells\u2019. Leuk Res 25:661\u2013663","journal-title":"Leuk Res"},{"key":"2236_CR32","first-page":"2023","volume":"8","author":"A Newman","year":"1994","unstructured":"Newman A, Clutterbuck RD, Powles RL, Millar JL (1994) Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia 8:2023\u20132029","journal-title":"Leukemia"},{"key":"2236_CR33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11745-997-0032-1","volume":"32","author":"S Vitols","year":"1997","unstructured":"Vitols S, Angelin B, Juliusson G (1997) Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans-in vitro and in vivo studies. Lipids 32:255\u2013262","journal-title":"Lipids"},{"key":"2236_CR34","doi-asserted-by":"crossref","first-page":"18568","DOI":"10.1016\/S0021-9258(17)44789-2","volume":"265","author":"JA Cuthbert","year":"1990","unstructured":"Cuthbert JA, Lipsky PE (1990) Inhibition by 6-fluoromevalonate demonstrates that mevalonate or one of the mevalonate phosphates is necessary for lymphocyte proliferation. J Biol Chem 265:18568\u201318575","journal-title":"J Biol Chem"},{"key":"2236_CR35","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0016-5085(92)90032-T","volume":"103","author":"S Sumi","year":"1992","unstructured":"Sumi S, Beauchamp RD, Townsend CJ, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC (1992) Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 103:982\u2013989","journal-title":"Gastroenterology"},{"key":"2236_CR36","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1158\/0008-5472.CAN-06-3686","volume":"67","author":"A Sassano","year":"2007","unstructured":"Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, Platanias LC (2007) Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 67:4524\u20134532","journal-title":"Cancer Res"},{"key":"2236_CR37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/07357900701208535","volume":"25","author":"H Bessler","year":"2007","unstructured":"Bessler H, Salman H, Bergman M, Djaldetti M (2007) On the factors modulating the effect of statins on malignant cell proliferation. Cancer Investig 25:279\u2013284","journal-title":"Cancer Investig"},{"key":"2236_CR38","first-page":"3602","volume":"51","author":"K Keyomarsi","year":"1991","unstructured":"Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51:3602\u20133609","journal-title":"Cancer Res"},{"key":"2236_CR39","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1073\/pnas.91.12.5291","volume":"91","author":"L Hengst","year":"1994","unstructured":"Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI (1994) A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A 91:5291\u20135295","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2236_CR40","first-page":"604","volume":"57","author":"J Gray-Bablin","year":"1997","unstructured":"Gray-Bablin J, Rao S, Keyomarsi K (1997) Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57:604\u2013609","journal-title":"Cancer Res"},{"key":"2236_CR41","doi-asserted-by":"crossref","first-page":"10618","DOI":"10.1074\/jbc.273.17.10618","volume":"273","author":"SJ Lee","year":"1998","unstructured":"Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim SJ, Trepel JB (1998) Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1\/CIP1) in human prostate carcinoma cells. J Biol Chem 273:10618\u201310623","journal-title":"J Biol Chem"},{"key":"2236_CR42","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/sj.onc.1202322","volume":"17","author":"S Rao","year":"1998","unstructured":"Rao S, Lowe M, Herliczek TW, Keyomarsi K (1998) Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17:2393\u20132402","journal-title":"Oncogene"},{"key":"2236_CR43","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/carcin\/22.7.1061","volume":"22","author":"A W\u00e4chtersh\u00e4user","year":"2001","unstructured":"W\u00e4chtersh\u00e4user A, Akoglu B, Stein J (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22:1061\u20131067","journal-title":"Carcinogenesis"},{"key":"2236_CR44","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbrc.2005.11.075","volume":"339","author":"J Lee","year":"2006","unstructured":"Lee J, Lee I, Park C, Kang WK (2006) Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem Biophys Res Commun 339:748\u2013754","journal-title":"Biochem Biophys Res Commun"},{"key":"2236_CR45","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1006\/bbrc.1994.1359","volume":"199","author":"D P\u00e9rez-Sala","year":"1994","unstructured":"P\u00e9rez-Sala D, Mollinedo F (1994) Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 199:1209\u20131215","journal-title":"Biochem Biophys Res Commun"},{"key":"2236_CR46","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.V93.4.1308","volume":"93","author":"J Dimitroulakos","year":"1999","unstructured":"Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ (1999) Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93:1308\u20131318","journal-title":"Blood"},{"key":"2236_CR47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1034\/j.1600-0773.2000.d01-16.x","volume":"86","author":"IK Wang","year":"2000","unstructured":"Wang IK, Lin-Shiau SY, Lin JK (2000) Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol 86:83\u201391","journal-title":"Pharmacol Toxicol"},{"key":"2236_CR48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2310\/6650.2001.33896","volume":"49","author":"M Lishner","year":"2001","unstructured":"Lishner M, Bar-Sef A, Elis A, Fabian I (2001) Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines. J Investig Med 49:319\u2013324","journal-title":"J Investig Med"},{"key":"2236_CR49","first-page":"2067","volume":"7","author":"WW Wong","year":"2001","unstructured":"Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ (2001) Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 7:2067\u20132075","journal-title":"Clin Cancer Res"},{"key":"2236_CR50","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jpba.2005.04.022","volume":"39","author":"N Yasuda","year":"2005","unstructured":"Yasuda N, Matzno S, Iwano C, Nishikata M, Matsuyama K (2005) Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry. J Pharm Biomed Anal 39:712\u2013717","journal-title":"J Pharm Biomed Anal"},{"key":"2236_CR51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2141.2011.08696.x","volume":"155","author":"C Sheen","year":"2011","unstructured":"Sheen C, Vincent T, Barrett D, Horwitz EM, Hulitt J, Strong E, Grupp SA, Teachey DT (2011) Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis. Br J Haematol 155:403\u2013407","journal-title":"Br J Haematol"},{"key":"2236_CR52","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0301-472X(03)00192-9","volume":"31","author":"D Chapman-Shimshoni","year":"2003","unstructured":"Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M (2003) Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 31:779\u2013783","journal-title":"Exp Hematol"},{"key":"2236_CR53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000235907","volume":"84","author":"YC Yang","year":"2009","unstructured":"Yang YC, Xiao DW, Liu H, Chuan LM, Zeng YL, Zhou DA, Liu W, Xu GQ, Huang WF (2009) Mechanism of simvastatin-induced K562 cell apoptosis. Pharmacology 84:191\u2013195","journal-title":"Pharmacology"},{"key":"2236_CR54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2310\/6650.2004.03057","volume":"52","author":"N Gronich","year":"2004","unstructured":"Gronich N, Drucker L, Shapiro H, Radnay J, Yarkoni S, Lishner M (2004) Simvastatin induces death of multiple myeloma cell lines. J Investig Med 52:335\u2013344","journal-title":"J Investig Med"},{"key":"2236_CR55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/carcin\/bgi036","volume":"26","author":"P Cafforio","year":"2005","unstructured":"Cafforio P, Dammacco F, Gernone A, Silvestris F (2005) Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26:883\u2013891","journal-title":"Carcinogenesis"},{"key":"2236_CR56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.yexcr.2008.10.010","volume":"315","author":"M Nonaka","year":"2009","unstructured":"Nonaka M, Uota S, Saitoh Y, Takahashi M, Sugimoto H, Amet T, Arai A, Miura O, Yamamoto N, Yamaoka S (2009) Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res 315:141\u2013150","journal-title":"Exp Cell Res"},{"key":"2236_CR57","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.leu.2402196","volume":"15","author":"Z Xia","year":"2001","unstructured":"Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2001) Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15:1398\u20131407","journal-title":"Leukemia"},{"key":"2236_CR58","first-page":"5735","volume":"9","author":"NWCJ Donk van de","year":"2003","unstructured":"van de Donk NWCJ, Schotte D, Kamphuis MMJ, van Marion AM, van Kessel B, Bloem AC, Lokhorst HM (2003) Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res 9:5735\u20135748","journal-title":"Clin Cancer Res"},{"key":"2236_CR59","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood-2003-03-0970","volume":"102","author":"NWCJ Donk van de","year":"2003","unstructured":"van de Donk NWCJ, Kamphuis MMJ, van Kessel B, Lokhorst HM, Bloem AC (2003) Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 102:3354\u20133362","journal-title":"Blood"},{"key":"2236_CR60","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1158\/0008-5472.CAN-04-0866","volume":"64","author":"J Wu","year":"2004","unstructured":"Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ (2004) Blocking the Raf\/MEK\/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64:6461\u20136468","journal-title":"Cancer Res"},{"key":"2236_CR61","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2002-07-2283","volume":"101","author":"HY Li","year":"2003","unstructured":"Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE (2003) Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101:3628\u20133634","journal-title":"Blood"},{"key":"2236_CR62","first-page":"2223","volume":"5","author":"B Agarwal","year":"1999","unstructured":"Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR (1999) Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 5:2223\u20132229","journal-title":"Clin Cancer Res"},{"key":"2236_CR63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/10428190009054894","volume":"40","author":"J Dimitroulakos","year":"2000","unstructured":"Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ (2000) Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 40:167\u2013178","journal-title":"Leuk Lymphoma"},{"key":"2236_CR64","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.leu.2402476","volume":"16","author":"WW Wong","year":"2002","unstructured":"Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508\u2013519","journal-title":"Leukemia"},{"key":"2236_CR65","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/386671a0","volume":"386","author":"W Risau","year":"1997","unstructured":"Risau W (1997) Mechanisms of angiogenesis. Nature 386:671\u2013674","journal-title":"Nature"},{"key":"2236_CR66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(99)00525-2","volume":"35","author":"CJ Vaughan","year":"2000","unstructured":"Vaughan CJ, Gotto AM Jr, Basson CT (2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35:1\u201310","journal-title":"J Am Coll Cardiol"},{"key":"2236_CR67","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0008-6363(00)00146-2","volume":"47","author":"K Koh","year":"2000","unstructured":"Koh K (2000) Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648\u2013657","journal-title":"Cardiovasc Res"},{"key":"2236_CR68","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0735-1097(01)01430-9","volume":"38","author":"M Weis","year":"2001","unstructured":"Weis M, Pehlivanli S, Meiser BM, von Scheidt W (2001) Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation after heart transplantation. J Am Coll Cardiol 38:814\u2013818","journal-title":"J Am Coll Cardiol"},{"key":"2236_CR69","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/hc0602.103393","volume":"105","author":"M Weis","year":"2002","unstructured":"Weis M, Heeschen C, Glassford AJ, Cooke JP (2002) Statins have biphasic effect on angiogenesis. Circulation 105:739\u2013745","journal-title":"Circulation"},{"key":"2236_CR70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1440-1681.1999.03029.x","volume":"26","author":"MS Goligorsky","year":"1999","unstructured":"Goligorsky MS, Budzikowski AS, Tsukahara H, Noiri E (1999) Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 26:269\u2013271","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2236_CR71","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/79510","volume":"6","author":"Y Kureishi","year":"2000","unstructured":"Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004\u20131010","journal-title":"Nat Med"},{"key":"2236_CR72","doi-asserted-by":"crossref","first-page":"e12563","DOI":"10.1371\/journal.pone.0012563","volume":"5","author":"TT Zhao","year":"2010","unstructured":"Zhao TT, Trinh D, Addison CL, Dimitroulakos J (2010) Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors. PLoS One 5:e12563","journal-title":"PLoS One"},{"key":"2236_CR73","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.leukres.2008.01.008","volume":"32","author":"S Paydas","year":"2008","unstructured":"Paydas S, Ergin M, Erdogan S, Seydaoglu G (2008) Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin\u2019s lymphomas. Leuk Res 32:1424\u20131430","journal-title":"Leuk Res"},{"key":"2236_CR74","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s12032-011-0008-8","volume":"29","author":"L Xie","year":"2012","unstructured":"Xie L, Shen LD, Qing C, Yang ZZ, Li K, Li Y, Yang JL (2012) Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma. Med Oncol 29:1711\u20131715","journal-title":"Med Oncol"},{"key":"2236_CR75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3727\/096504011X12935427587885","volume":"19","author":"HM Li","year":"2011","unstructured":"Li HM, Long Y, Qing C, Yu M, Li ZH, Zhang XM, Li XJ, Chen YJ, Zhang YL, Liang Y (2011) Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis. Oncol Res 19:149\u2013163","journal-title":"Oncol Res"},{"key":"2236_CR76","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/annonc\/mdm579","volume":"19","author":"D Aguiar Bujanda","year":"2008","unstructured":"Aguiar Bujanda D (2008) Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 19:396\u2013397","journal-title":"Ann Oncol"},{"key":"2236_CR77","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3324\/haematol.2010.037689","volume":"96","author":"L Wang","year":"2011","unstructured":"Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, Shen ZX, Chen SJ, Leboeuf C, Janin A, Zhao WL (2011) Bevacizumab potentiates chemotherapeutic effect on T-leukemia\/lymphoma cells by direct action on tumor endothelial cells. Haematologica 96:927\u2013931","journal-title":"Haematologica"},{"key":"2236_CR78","doi-asserted-by":"crossref","first-page":"6978","DOI":"10.1158\/1078-0432.CCR-06-1140","volume":"12","author":"IA Avramis","year":"2006","unstructured":"Avramis IA, Panosyan EH, Dorey F, Holcenberg JS, Avramis VI (2006) Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study CCG- 1962. Clin Cancer Res 12:6978\u20136984","journal-title":"Clin Cancer Res"},{"key":"2236_CR79","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-03-0627","volume":"10","author":"JE Karp","year":"2004","unstructured":"Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, Chen H, Zwiebel J (2004) Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabino\u2014furanosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 10:3577\u20133585","journal-title":"Clin Cancer Res"},{"key":"2236_CR80","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.clinbiochem.2011.01.010","volume":"44","author":"S Joshi","year":"2001","unstructured":"Joshi S, Khan R, Sharma M, Kumar L, Sharma A (2001) Angiopoietin-2: a potential novel diagnostic marker in multiple myeloma. Clin Biochem 44:590\u2013595","journal-title":"Clin Biochem"},{"key":"2236_CR81","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0145-2126(00)00162-4","volume":"25","author":"SA Holstein","year":"2001","unstructured":"Holstein SA, Hohl RJ (2001) Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res 25:651\u2013660","journal-title":"Leuk Res"},{"key":"2236_CR82","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2141.2008.07257.x","volume":"142","author":"AS Moreau","year":"2008","unstructured":"Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O\u2019Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP (2008) The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol 142:775\u2013785","journal-title":"Br J Haematol"},{"key":"2236_CR83","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-010-0988-z","volume":"89","author":"M Podhorecka","year":"2010","unstructured":"Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszynska A (2010) Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol 89:1115\u20131124","journal-title":"Ann Hematol"},{"key":"2236_CR84","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ijc.10440","volume":"100","author":"W Feleszko","year":"2002","unstructured":"Feleszko W, M\u0142ynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, Hoser G, Korczak-Kowalska G, Jak\u00f3bisiak M (2002) Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 100:111\u2013118","journal-title":"Int J Cancer"},{"key":"2236_CR85","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1124\/mol.108.045286","volume":"74","author":"C Riganti","year":"2008","unstructured":"Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A (2008) Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol 74:476\u2013484","journal-title":"Mol Pharmacol"},{"key":"2236_CR86","first-page":"2044","volume":"6","author":"W Feleszko","year":"2000","unstructured":"Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, Giermasz A, Jak\u00f3bisiak M (2000) Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 6:2044\u20132052","journal-title":"Clin Cancer Res"},{"key":"2236_CR87","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2407-10-103","volume":"10","author":"A Martirosyan","year":"2010","unstructured":"Martirosyan A, Clendening JW, Goard CA, Penn LZ (2010) Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 10:103","journal-title":"BMC Cancer"},{"key":"2236_CR88","first-page":"727","volume":"150","author":"N Iliskovic","year":"1997","unstructured":"Iliskovic N, Singal PK (1997) Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 150:727\u2013734","journal-title":"Am J Pathol"},{"key":"2236_CR89","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.bcp.2007.10.010","volume":"75","author":"KS Ahn","year":"2008","unstructured":"Ahn KS, Sethi G, Aggarwal BB (2008) Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol 75:907\u2013913","journal-title":"Biochem Pharmacol"},{"key":"2236_CR90","first-page":"1205","volume":"19","author":"VR Rozados","year":"2008","unstructured":"Rozados VR, Hinrichsen LI, Binda MM, Gervasoni SI, Matar P, Bonfil RD, Scharovsky OG (2008) Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models. Oncol Rep 19:1205\u20131211","journal-title":"Oncol Rep"},{"key":"2236_CR91","first-page":"542","volume":"91","author":"E Spek van der","year":"2006","unstructured":"van der Spek E, Bloem AC, van de Donk NW, Bogers LH, van der Griend R, Kramer MH, de Weerdt O, Wittebol S, Lokhorst HM (2006) Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 91:542\u2013545","journal-title":"Haematologica"},{"key":"2236_CR92","first-page":"141","volume":"1","author":"SA Holstein","year":"2001","unstructured":"Holstein SA, Hohl RJ (2001) Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 1:141\u2013149","journal-title":"Mol Cancer Ther"},{"key":"2236_CR93","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.leukres.2008.06.001","volume":"33","author":"E Spek van der","year":"2009","unstructured":"van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Bogers-Boer L, van de Donk NW (2009) Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 33:100\u2013108","journal-title":"Leuk Res"},{"key":"2236_CR94","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00228-006-0106-2","volume":"62","author":"A Dmoszynska","year":"2006","unstructured":"Dmoszynska A, Podhorecka M, Klimek P, Grzasko N (2006) Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. Eur J Clin Pharmacol 62:325\u2013329","journal-title":"Eur J Clin Pharmacol"},{"key":"2236_CR95","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1371\/journal.pmed.0050064","volume":"5","author":"M Winiarska","year":"2008","unstructured":"Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus WJ, Gorska E, Bojarski L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M, Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-Iwanicka A, Basak GW, Wasik M, Warzocha K, Sinski M, Gaciong Z, Jakobisiak M, Parren PW, Golab J (2008) Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 5:e64","journal-title":"PLoS Med"},{"key":"2236_CR96","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00277-010-0926-0","volume":"89","author":"P Samaras","year":"2010","unstructured":"Samaras P, Heider H, Haile SR, Petrausch U, Schaefer NG, Siciliano RD, Meisel A, Mischo A, Zweifel M, Knuth A, Stenner-Liewen F, Renner C (2010) Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Ann Hematol 89:783\u2013787","journal-title":"Ann Hematol"},{"key":"2236_CR97","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2009.23.4245","volume":"28","author":"GS Nowakowski","year":"2010","unstructured":"Nowakowski GS, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, Allmer C, Slager SL, Witzig TE, Cerhan JR (2010) Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 28:412\u2013417","journal-title":"J Clin Oncol"},{"key":"2236_CR98","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358\u20133363","journal-title":"J Clin Oncol"},{"key":"2236_CR99","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12618","volume":"164","author":"MW Deininger","year":"2014","unstructured":"Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ (2014) Imatinib 800\u00a0mg daily induces deeper molecular responses than imatinib 400\u00a0mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223\u2013232","journal-title":"Br J Haematol"},{"key":"2236_CR100","first-page":"528","volume":"28","author":"R Chen","year":"2011","unstructured":"Chen R, Xiao W, Li D, Mu S (2011) Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. Med Oncol 28:528\u2013531","journal-title":"Med Oncol"},{"key":"2236_CR101","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/CAD.0b013e32835a0fbd","volume":"24","author":"B Oh","year":"2013","unstructured":"Oh B, Kim TY, Min HJ, Kim M, Kang MS, Huh JY, Kim Y, Lee DS (2013) Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells. Anticancer Drugs 24:20\u201331","journal-title":"Anticancer Drugs"},{"key":"2236_CR102","first-page":"313","volume":"3","author":"P Norman","year":"2002","unstructured":"Norman P (2002) Tipifarnib. Curr Opin Investig Drugs 3:313\u2013319","journal-title":"Curr Opin Investig Drugs"},{"key":"2236_CR103","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","volume":"97","author":"JE Karp","year":"2001","unstructured":"Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J (2001) Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase1clinical-laboratory correlative trial. Blood 97:3361\u20133369","journal-title":"Blood"},{"key":"2236_CR104","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.2008.07099.x","volume":"141","author":"T Braun","year":"2008","unstructured":"Braun T, Fenaux P (2008) Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 141:576\u2013586","journal-title":"Br J Haematol"},{"key":"2236_CR105","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-01-198093","volume":"114","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ (2009) A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70\u00a0years or older. Blood 114:1166\u20131173","journal-title":"Blood"},{"key":"2236_CR106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/13543781003801076","volume":"19","author":"PK Epling-Burnette","year":"2010","unstructured":"Epling-Burnette PK, Loughran TP Jr (2010) Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. Expert Opin Investig Drugs 19:689\u2013698","journal-title":"Expert Opin Investig Drugs"},{"key":"2236_CR107","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1074\/jbc.272.22.14459","volume":"272","author":"DB Whyte","year":"1997","unstructured":"Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK (1997) K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459\u201314464","journal-title":"J Biol Chem"},{"key":"2236_CR108","first-page":"3078","volume":"15","author":"K Weide Van der","year":"2009","unstructured":"Van der Weide K, Jonge-Peeters S, Kuipers K, de Vries EG, Vellenga E (2009) Combining Simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res 15:3078\u20133083","journal-title":"Clin Cancer Res"},{"key":"2236_CR109","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00277-011-1276-2","volume":"90","author":"M Hus","year":"2011","unstructured":"Hus M, Grzasko N, Szostek M, Pluta A, Helbig G, Woszczyk D, Adamczyk-Cioch M, Jawniak D, Legiec W, Morawska M, Kozinska J, Waci\u0144ski P, Dmoszynska A (2011) Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Ann Hematol 90:1161\u20131166","journal-title":"Ann Hematol"},{"key":"2236_CR110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.869","volume":"27","author":"TE Sondergaard","year":"2009","unstructured":"Sondergaard TE, Pedersen PT, Andersen TL, Soe K, Lund T, Ostergaard B, Garnero P, Delaisse JM, Plesner T (2009) A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. Hematol Oncol 27:17\u201322","journal-title":"Hematol Oncol"},{"key":"2236_CR111","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.3324\/haematol.12071","volume":"92","author":"E Spek van der","year":"2007","unstructured":"van der Spek E, Bloem AC, Sinnige HA, Lokhorst HM (2007) High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica 92:e130\u2013e131","journal-title":"Haematologica"},{"key":"2236_CR112","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood-2006-08-044446","volume":"109","author":"SM Kornblau","year":"2007","unstructured":"Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, Jackson CE, Chen W, Estey E, Appelbaum FR (2007) Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin+high-dose Ara-C: a phase 1 study. Blood 109:2999\u20133006","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2236-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2236-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T15:42:54Z","timestamp":1650728574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2236-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,23]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2236-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,23]]}}}